TY  - JOUR
PY  - 2014//
TI  - Extended-release hydrocodone: the devil in disguise or just misunderstood?
JO  - Annals of pharmacotherapy
A1  - Schweighardt, Anne E.
A1  - Juba, Katherine M.
SP  - 1362
EP  - 1365
VL  - 48
IS  - 10
N2  - Opioid abuse in the United States increased significantly over the past decade, leading to opioid-related deaths. Approval of Zohydro ER, a product that lacks an abuse-deterrent formulation, has provoked media controversy and aggressive legislative action from multiple stakeholders. Only the American Academy of Pain Management has released a position statement on this medication, and individual opinion varies. Additional single-entity extended-release hydrocodone formulations are in the pipeline, and Zohydro ER's limited clinical utility may make the controversy associated with its approval a moot point. As with other opioids, providers will need to assess individual patient risk versus benefit when prescribing Zohydro ER.    Keywords: Social Transition<p />  <p>Language: en</p>
LA  - en
SN  - 1060-0280
UR  - http://dx.doi.org/10.1177/1060028014543174
ID  - ref1
ER  -